This stock like most bio companies can run fast on good news but bad news it crashes. I was in years ago. It was a $3 stock and opened up at $6 or $7. Then they had another drug that didn’t get approved and it became a .50 cent stock. A RS had to happen because the stock exchange was going to pull them off of the exchange unless they got the price above $3. They ran to $20 on this new drug. Now this happened and we are back at $1. They had a net worth of about $400 million. They just one good report on their other drug developments and we will be back to $20 in no time.
News 
Market Data 
Discover 
